Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Abstract

We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-induced eosinophil reduction; thus, prior favorable responses to mepolizumab may predict benralizumab efficacy. Keywords: Benralizumab, Mepolizumab, Severe asthma, Eosinophil